DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) CEO Saiid Zarrabian purchased 60,900 shares of the business’s stock in a transaction on Tuesday, November 14th. The stock was acquired at an average cost of $0.82 per share, with a total value of $49,938.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) traded down $0.01 during midday trading on Thursday, reaching $0.80. 203,816 shares of the company’s stock were exchanged, compared to its average volume of 376,119. DelMar Pharmaceuticals, Inc. has a 52 week low of $0.78 and a 52 week high of $5.39.
DelMar Pharmaceuticals (NASDAQ:DMPI) last issued its quarterly earnings results on Monday, November 13th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.17) by ($0.01). equities research analysts anticipate that DelMar Pharmaceuticals, Inc. will post -0.61 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Insider Buying: DelMar Pharmaceuticals, Inc. (DMPI) CEO Acquires 60,900 Shares of Stock” was published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this report on another domain, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The correct version of this report can be read at https://transcriptdaily.com/2017/11/17/insider-buying-delmar-pharmaceuticals-inc-dmpi-ceo-acquires-60900-shares-of-stock.html.
A number of equities research analysts have weighed in on DMPI shares. HC Wainwright set a $12.00 price target on shares of DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Monday, October 16th. Maxim Group reissued a “hold” rating on shares of DelMar Pharmaceuticals in a report on Monday, September 11th. Finally, Dawson James reissued a “buy” rating on shares of DelMar Pharmaceuticals in a report on Tuesday, August 8th.
A hedge fund recently bought a new stake in DelMar Pharmaceuticals stock. Sabby Management LLC acquired a new position in shares of DelMar Pharmaceuticals, Inc. (NASDAQ:DMPI) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 645,390 shares of the company’s stock, valued at approximately $1,484,000. Sabby Management LLC owned 4.79% of DelMar Pharmaceuticals at the end of the most recent quarter. 8.23% of the stock is owned by institutional investors and hedge funds.
About DelMar Pharmaceuticals
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.